HIV Drugs Market to Exhibit 5.9% CAGR till 2028; Hetero Unveils TAFFIC 3-in-one Antiretroviral Combination Drug to Lower the Amount of HIV in a Patient’s Blood

The global HIV drugs market size is projected to grow from USD 30.46 billion in 2021 to USD 45.58 billion in 2028. The emergence of new ATLAS regimens is expected to improve the compliance rates. The latest injectable formulation has already entered the global market and has surged the standard of care, unlike the commonly prescribed drugs. It has also reduced the dosing days to 12 days per year from 365 days. This information is given by Fortune Business Insights™, in a report, titled, “HIV Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Integrase Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Combination HIV Medicines, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2021-2028.” The report further mentions that the market stood at USD 28.79 billion in 2020. It is set to exhibit a CAGR of 5.9% in the forecast period between 2021-2028.

Merck Receives Approval from U.S. FDA for PIFELTRO and DELSTRIGO

In September 2019, Merck announced that it received the U.S. FDA approval for DELSTRIGO™ (as a complete regimen) and PIFELTRO™ (in combination with other antiretroviral agents). These will be used in adult patients for the treatment of HIV-1 infection. These patients will have to be suppressed on a stable antiretroviral regimen with no history of substitutions related to the resistance to both drugs and treatment failures. As per one of the company officials, “These broadened indications would help certain people with HIV-1 infection to move towards PIFELTRO and DELSTRIGO from their current antiretroviral therapy by combining other antiretroviral agents.” Such initiatives by reputed players would bolster the demand for these drugs in the near future.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115

Increasing Cases of HIV Infections to Boost Demand for HIV Drugs Worldwide

In developing regions, such as Africa, the cases of HIV infections are surging rapidly. It is set to drive the HIV drugs market growth. The World Health Organization (WHO) mentioned that in 2019, 1.7 million new HIV-infected patients were reported, while 33.0 million people were living with the infection globally. Besides, the Joint United Nations Programme on HIV/AIDS (UNAIDS) stated that in 2019, there were approximately 5.8 million HIV-infected individuals in Asia Pacific, 20.7 million people in Eastern and Southern Africa, and 2.2 million people in Western & Central Europe and North America. However, the ongoing COVID-19 pandemic has resulted in the reduced demand for antiretroviral drugs, which, in turn, may hamper growth.

Key Companies Aim to Improve Their Product Portfolios through New Launches

The global market contains various companies, such as Merck Sharp & Dohme Corp., Janssen Pharmaceuticals, Inc., Gilead Sciences, and ViiV Healthcare. They are majorly focusing on new product launches and collaborative efforts to enhance their pre-existing product portfolios. A few others are also trying to win approvals for their in-house products from government agencies to distribute them in the market.

A Notable Industry Development-

• December 2019: Hetero introduced TAFFIC, its new 3-in-1 antiretroviral combination drug in India. The company received approval for the same from the Drug Controller General of India (DCGI) and is a generic version of Biktarvy, a drug of Gilead. It would help to lower the amount of HIV in a patient’s blood and enhance their quality of life.

Further Report Findings-

• In 2020, North America generated USD 20.27 billion in terms of revenue. The region is anticipated to lead the market in the upcoming years because of the increasing awareness among people regarding the availability of various effective HIV drugs. At the same time, the higher prevalence of HIV infection in the U.S. would also propel growth.


• Europe is set to remain in the second position, followed by North America owing to the rising collaborative efforts happening among major vendors of HIV drugs in the region. In July 2020, for instance, Theratechnologies Europe Limited and Loxxess joined hands for the distribution of an antiretroviral drug named Trogarzo in Europe.


• By the drug class, the combination HIV medicines segment is set to remain dominant throughout the forthcoming years. This growth is attributable to the rising usage of this type of drugs for achieving better results in the management of HIV infections. The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment held the lowest HIV drugs market share of 5.6% in 2020.

Fortune Business Insights™ presents a list of renowned manufacturers of HIV drugs present in the global market. They are as follows:

• 
  
  
  
  • ViiV Healthcare (Research Triangle Park, U.S.)
  
  
  • Gilead Sciences, Inc. (Foster City, U.S.)
  
  
  • GlaxoSmithKline plc (Brentford, U.K.)
  
  
  • Merck Sharp & Dohme Corp. (Kenilworth, France)
  
  
  • Bristol-Myers Squibb Company (New York City, U.S.)
  
  
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Beerse, Belgium)
  
  
  • Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany)
  
  
  • AbbVie Inc. (North Chicago, U.S.)
  
  
  • Genentech, Inc. (F. Hoffmann-La Roche AG) (South San Francisco, U.S.)
  
  
  • Mylan N.V. (Canonsburg, U.S.)
  
  
  • Other Prominent Players
  
  
  
  

The global market can be segmented in this way: